Dauricine induces ferroptosis in neuroblastoma by inhibiting methyltransferase-like 1-mediated N7-methylguanosine methylation of solute carrier family 3 member 2

Neuroblastoma is one of the most common extracranial solid tumors in children, characterized by high heterogeneity, aggressive biological behavior, and poor clinical prognosis. Ferroptosis, a form of programmed cell death driven by iron accumulation and lipid peroxidation, has been reported to be closely associated with neuroblastoma progression. Dauricine (Dau), a bisbenzylisoquinoline alkaloid extracted from traditional Chinese medicine, has demonstrated antitumor activity, but its role in regulating ferroptosis in neuroblastoma remains unclear. Cell viability, apoptosis, invasion, stemness, and angiogenesis were evaluated using 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, terminal deoxynucleotidyl transferase dUTP nick end labeling, transwell, sphere formation, and tube formation assays, respectively. Ferroptosis-related indicators were detected using corresponding commercial kits. The methyltransferase-like 1 (METTL1)-mediated N7-methylguanosine (m7G) methylation of solute carrier family 3 member 2 (SLC3A2) was examined through methylated RNA immunoprecipitation. RNA immunoprecipitation and RNA pull-down assays were conducted to confirm the interaction between METTL1 and SLC3A2 mRNA. Real-time quantitative PCR and western blotting were utilized to assess mRNA and protein expression, respectively. Molecular docking was performed to evaluate the potential binding interaction between Dau and METTL1. A xenograft tumor model was used for in vivo validation. The results showed that Dau inhibited neuroblastoma cell progression and promoted ferroptosis, while overexpression of SLC3A2 countered these effects. METTL1 mediated the m7G methylation of SLC3A2. Overexpression of SLC3A2 reversed the inhibition of neuroblastoma cell progression and the promotion of ferroptosis caused by METTL1 knockdown. Dau suppressed METTL1 expression, thus inhibiting neuroblastoma cell progression and promoting ferroptosis. Additionally, Dau reduced tumor growth in vivo. Together, Dau enhanced ferroptosis and impeded neuroblastoma development by suppressing METTL1-mediated m7G methylation of SLC3A2, suggesting a novel therapeutic strategy for neuroblastoma.

Authors

Institutions

Publication Details

Journal
Anti-Cancer Drugs
Published
2026-01-14
DOI
https://doi.org/10.1097/cad.0000000000001809
Primary Topic
Ferroptosis and cancer prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Dauricine induces ferroptosis in neuroblastoma by inhibiting methyltransferase-like 1-mediated N7-methylguanosine methylation of solute carrier family 3 member 2

Liping Tang, Na Huang, Lifen Ren, Tianyun Li
Anti-Cancer Drugs
Ferroptosis and cancer prognosis
article

Dauricine induces ferroptosis in neuroblastoma by inhibiting methyltransferase-like 1-mediated N7-methylguanosine methylation of solute carrier family 3 member 2

Liping Tang, Na Huang, Lifen Ren, Tianyun Li
article en

Abstract

Neuroblastoma is one of the most common extracranial solid tumors in children, characterized by high heterogeneity, aggressive biological behavior, and poor clinical prognosis. Ferroptosis, a form of programmed cell death driven by iron accumulation and lipid peroxidation, has been reported to be closely associated with neuroblastoma progression. Dauricine (Dau), a bisbenzylisoquinoline alkaloid extracted from traditional Chinese medicine, has demonstrated antitumor activity, but its role in regulating ferroptosis in neuroblastoma remains unclear. Cell viability, apoptosis, invasion, stemness, and angiogenesis were evaluated using 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, terminal deoxynucleotidyl transferase dUTP nick end labeling, transwell, sphere formation, and tube formation assays, respectively. Ferroptosis-related indicators were detected using corresponding commercial kits. The methyltransferase-like 1 (METTL1)-mediated N7-methylguanosine (m7G) methylation of solute carrier family 3 member 2 (SLC3A2) was examined through methylated RNA immunoprecipitation. RNA immunoprecipitation and RNA pull-down assays were conducted to confirm the interaction between METTL1 and SLC3A2 mRNA. Real-time quantitative PCR and western blotting were utilized to assess mRNA and protein expression, respectively. Molecular docking was performed to evaluate the potential binding interaction between Dau and METTL1. A xenograft tumor model was used for in vivo validation. The results showed that Dau inhibited neuroblastoma cell progression and promoted ferroptosis, while overexpression of SLC3A2 countered these effects. METTL1 mediated the m7G methylation of SLC3A2. Overexpression of SLC3A2 reversed the inhibition of neuroblastoma cell progression and the promotion of ferroptosis caused by METTL1 knockdown. Dau suppressed METTL1 expression, thus inhibiting neuroblastoma cell progression and promoting ferroptosis. Additionally, Dau reduced tumor growth in vivo. Together, Dau enhanced ferroptosis and impeded neuroblastoma development by suppressing METTL1-mediated m7G methylation of SLC3A2, suggesting a novel therapeutic strategy for neuroblastoma.

Anti-Cancer Drugs
Xi'an Medical University (CN), Xijing Hospital (CN), Air Force Medical University (CN)
Good health and well-being
Openalex Percentile: Top 86%
Ferroptosis and cancer prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.